BANK VONTOBEL/CALL/NOVO NORDISK ADR B/160/0.1/20.09.24 | Market Closed - Boerse Frankfurt Warrants 01:44:33 2024-06-14 pm EDT | ||
| 0.35 EUR | +12.90% |
|
| Current month | +84.21% | ||
| 1 month | +56.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 0.35 | +12.90% |
| 24-06-13 | 0.31 | -11.43% |
| 24-06-12 | 0.35 | +6.06% |
| 24-06-11 | 0.33 | -13.16% |
| 24-06-10 | 0.38 | -2.56% |
Real-time Boerse Frankfurt Warrants
Last update June 14, 2024 at 01:44 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1SG9 |
| ISIN | DE000VD1SG97 |
| Date issued | 2024-03-07 |
| Strike | 160 $ |
| Maturity | 2024-09-20 (97 Days) |
| Parity | 10 : 1 |
| Emission price | 0.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.65 € |
|---|---|
| Lowest since issue | 0.131 € |
| Spread | 0.01 € |
| Spread % | 2.86% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
991
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.72%
- Stock Market
- Warrants
- Warrant
